Uk healthcare

Vietnamese company Huro Probiotics will cooperate in the UK research of a COVID-19 medicine According to information posted on the London Stock Exchange on September 7, Destiny Pharma and SporeGen has entered a cooperation in the research and development (R&D) of products from bacteria, called SPORE-COV, that can stimulate the natural immune system and fight against the SARS-COV-2 virus. The representative of Destiny Pharma said that the project will have the participation of a Vietnamese enterprise, Huro Probiotics – a member of The PAN Group (HSX: PAN) as material provider and developer of standardised manufacturing technology on an industrial scale. Destiny Pharma, which specialises in the development of a new generation of anti-infection drugs, and SporeGen, which specialises in the application of microbiological spores from the UK, will play a key role in the COVID-19 room product creation project. The British government has also decided to finance £800,000 ($1 million) out of a total of £1.1 million ($1.4 million) with the desire to soon get a low-cost anti-epidemic product for the people. SPOR-COV was developed from a Sporegen exclusive formulation based on a naturally isolated non-pathogenic bacterium that is administered nasally as a spray. Unlike vaccines, SPOR-COV focuses on utilising the natural (innate) immune system to enhance protection against the SARS-CoV-2 virus a few days after dosing. The only Vietnamese company participating in the project, Huro Probiotics, formerly the R&D center of The PAN Group, was established in 2012, specializing in research, development and production of probiotics for the pharmaceutical and food industries. One of the prominent product applications of the group is the first gummy product in Vietnam incorporating probiotic strain HU58. The UK's experience in cooperation and technology transfer from many years ago can be one of the opportunities to help the PAN Group participate in the SPOR-COV …

[Read more...] about Huro Probiotics participates in UK research of COVID-19 medication

Prof. Do Quyet, director of the Vietnam Military Medical Academy, outlined the information as part of a brief announcement during the launch of the second phase of human clinical trials on Nano Covax which took place on February 26 in Hanoi. “Preliminary research results show that the potent antibodies elicited by Nano Covax prove to be effective against the variant B.1.1.7 from the UK,” said Prof. Quyet. The country kick-started the initial phase of human trials of Nano Covax last December, marking the first vaccine of its kind to be produced locally by Nanogen Pharmaceutical Biotechnology JSC, one of the four COVID-19 vaccine producers currently operating in the country. It is now in the process of launching the second phase of trials in both Hanoi and the southern province of Long An with the participation of approximately 560 volunteers aged between 12 and 75. The second phase is set to be focused on the safety and efficiency of the vaccine, especially the generation of antibodies, as the vaccine will also be tested on elderly people suffering from underlying health issues, according to Prof. Quyet. “In phase 2 we will continue to evaluate whether these antibodies can resist the variant from South Africa,” he said. Vietnamese scientists have conducted genome sequencing and found there are five variant strains of the SARS-CoV-2 virus since the initial COVID-19 outbreak erupted in January 2020. Most notably, variants VOC202012/01 and B.1.1.7 which originate from the UK and A.23.1 from South Africa have recently been detected at COVID-19 hotspots in Hai Duong province and Ho Chi Minh City, respectively. While locally-made vaccines are currently in the process of undergoing clinical trials, the country is striving to ramp up the import of COVID-19 vaccines as part of the national vaccination campaign. The initial batch of AstraZeneca vaccine arrived in Ho Chi Minh City on February 24, with more than 117,000 doses landing in the country. The …

[Read more...] about COVID-19: Made-in-Vietnam vaccine protects people against UK variant

The partnership helps those that live far from high-level hospitals At the Neonatal Intensive Care Unit (NICU) of Nghia Lo General Hospital, doctors are consistently providing active care for sick newborns, especially babies born prematurely to young mothers, the majority of whom are from ethnic minority groups. As a common practice, ethnic minority women still have to carry out heavy farming work whilst receiving inadequate nutrition during their pregnancy. The consequence is that many infants are prematurely born. As Dr. Nguyen Thi Ngoc Mai from the NICU explained, “Ethnic minority groups live in remote villages in mountainous areas which are hard to reach. It takes them hours to get to the NICU. As a result, many infants with infections come to our unit only in severe condition.” In 2014 the NICU was established in order to take better care of these children in the hospital without requiring at least four hours to travel to the central hospital. At the time, Mai and many other physicians lacked both professional expertise and proper medical equipment to take care of the sick new-born babies. To deal with this issue, GSK and Save the Children are cooperating to contribute to the development and operation of the NICU. Electrical equipment such as ventilators, automatic infusion machines, electric syringes, and monitors have been provided for the unit. In addition, 10 doctors and nurses have received training and practical experience at the National Children’s Hospital. With the support, Mai’s unit has helped save the lives of mothers and their babies from some of the most remote areas in the northern province of Yen Bai. One of them was a H’Mong baby boy. Three years ago, he was born prematurely at 31 weeks at home in a remote village in Yen Bai. At one day old, the baby was brought to the NICU in critical condition, with bluish discolouration on his skin and severe infections. At that moment, no-one thought that he could make it, but with the …

[Read more...] about Healthcare for the disadvantaged